Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: cornelissen jj. Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. Haematologica. 2015. PMID: 26341740 Free PMC article. Clinical Trial. No abstract available.
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ. van Esser JW, et al. Among authors: cornelissen jj. Blood. 2002 Jun 15;99(12):4364-9. doi: 10.1182/blood.v99.12.4364. Blood. 2002. PMID: 12036863 Free article. Clinical Trial.
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group. Segeren CM, et al. Among authors: cornelissen jj. Blood. 2003 Mar 15;101(6):2144-51. doi: 10.1182/blood-2002-03-0889. Epub 2002 Nov 27. Blood. 2003. PMID: 12456509 Free article. Clinical Trial.
Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MH, Barge RM, Schouten HC, Westveer PH, Steijaert MM, Cornelissen JJ, Sonneveld P; Dutch-Belgian Hemato-Oncology Cooperative Group. Lokhorst HM, et al. Among authors: cornelissen jj. J Clin Oncol. 2003 May 1;21(9):1728-33. doi: 10.1200/JCO.2003.04.033. J Clin Oncol. 2003. PMID: 12721248 Clinical Trial.
A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.
Cornelissen JJ, van der Holt B, Petersen EJ, Vindelov L, Russel CA, Höglund M, Maertens J, Schouten HC, Braakman E, Steijaert MM, Zijlmans MJ, Slaper-Cortenbach I, Boogaerts MA, Löwenberg B, Verdonck LF. Cornelissen JJ, et al. Exp Hematol. 2003 Oct;31(10):855-64. doi: 10.1016/s0301-472x(03)00195-4. Exp Hematol. 2003. PMID: 14550800 Free article. Clinical Trial.
A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE, van der Holt B, Haze S, Braakman E, Gratama JW, Löwenberg B, Cornelissen JJ. Broers AE, et al. Among authors: cornelissen jj. Exp Hematol. 2005 Aug;33(8):912-9. doi: 10.1016/j.exphem.2005.05.005. Exp Hematol. 2005. PMID: 16038784 Free article.
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM, Cornelissen JJ, Schouten HC, Ossenkoppele GJ, Verdonck LF; Netherlands Stem Cell Transplant Registry "TYPHON". van der Straaten HM, et al. Among authors: cornelissen jj. Haematologica. 2005 Oct;90(10):1339-45. Haematologica. 2005. PMID: 16219570
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.
Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Sonneveld P, et al. Among authors: cornelissen jj. Haematologica. 2007 Jul;92(7):928-35. doi: 10.3324/haematol.11168. Haematologica. 2007. PMID: 17606443 Free article. Clinical Trial.
441 results